-
公开(公告)号:US06903103B2
公开(公告)日:2005-06-07
申请号:US10369860
申请日:2003-02-20
申请人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号: C07D417/14 , A61K31/00 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/551 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P43/00 , C07D209/08 , C07D211/00 , C07D211/26 , C07D211/58 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/06 , C07D471/04 , C07D491/04 , C07D401/04 , C07D401/08 , C07D403/04
CPC分类号: C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译: 式(I)的化合物:其中:V表示单键或亚烷基链,M表示单键或亚烷基链,A和E各自表示氮或CH,但两个基团A或E中的至少一个表示 氮,W表示式(i),(ii)或(iii)的基团:其中:X表示羰基,磺酰基或亚砜,G 1,G 2和 G 3如说明书中所定义,T表示稠合的苯基或稠合的吡啶基,R 1表示直链或支链的C 1(C 1 H 3) 其中烷基部分是直链或烷基,其中烷基部分是直链或直链或支链烷基, 分支的R 2a和R 2b相同或不同,如说明书中所定义,R 3表示芳基或杂芳基 - 如在说明书中所定义的A,每个基团可以任选被取代,Y代表描述中定义的芳氧基,杂芳氧基或杂芳基-B,每个 h基团可任选被取代,其异构体,其水合物,其溶剂合物及其与药学上可接受的酸的加成盐。 含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。
-
公开(公告)号:US06566364B2
公开(公告)日:2003-05-20
申请号:US09751716
申请日:2000-12-29
申请人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号: C07D40112
CPC分类号: C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译: 式(I)的化合物:其中:V表示单键或亚烷基链,M表示单键或亚烷基链,A和E各自表示氮或CH,但两个基团A或E中的至少一个表示 氮,W表示式(i),(ii)或(iii)的基团:含有该基团的药物,其可用于治疗已知内皮功能障碍的疾病或病理状况。
-
公开(公告)号:US06486171B2
公开(公告)日:2002-11-26
申请号:US10105171
申请日:2002-03-25
IPC分类号: C07D47104
CPC分类号: C07D471/04 , C07D491/04 , C07D495/04
摘要: A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, or a group of formula Y (wherein) as defined in the description, n represents an integer from 1 to 6 inclusive, Z represents a single bond, oxygen, or optionally substituted nitrogen, A and Q each represent CH or nitrogen, it being understood that A or Q must be N and the other CH, M, together with a carbon of the phenyl to which it is bonded, represents thienyl, furyl, pyrrolyl, or oxopyrrolyl, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same, which are useful in the treatment of some CNS disorders.
摘要翻译: 选自式(I)的化合物:其中:W表示任选取代的萘基,或如说明书中所定义的式Y(其中)的基团,n表示1至6的整数,Z表示单键, 氧或任选取代的氮,A和Q各自表示CH或氮,应理解A或Q必须为N,另一个CH,M与其所键合的苯基的碳一起代表噻吩基,呋喃基 ,吡咯基或氧代吡咯基,其异构体及其药学上可接受的酸或碱加成盐,以及含有它们的药物,其可用于治疗一些CNS障碍。
-
公开(公告)号:US07470683B2
公开(公告)日:2008-12-30
申请号:US11904006
申请日:2007-09-25
IPC分类号: C07D498/04 , A61K31/53
CPC分类号: C07D498/04
摘要: Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH═CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.
摘要翻译: 式I化合物的反式相对构型:其中:X表示氧原子或NR 2基团,Y表示选自-CH 2 - , - (CH 2)2 - 和-CH-CH-,R 1和R 2的基团,其中 可以相同或不同,各自表示氢原子或选自烷基,环烷基和环烷基烷基的基团,其为外消旋形式或旋光异构体形式,以及其与药学上可接受的酸及其水合物的加成盐。 含有该药物的药物可用于治疗涉及多巴胺能系统的中枢神经系统疾病。
-
公开(公告)号:US06399616B1
公开(公告)日:2002-06-04
申请号:US09641777
申请日:2000-08-18
IPC分类号: A61K31496
CPC分类号: C07D471/04 , C07D491/04 , C07D495/04
摘要: A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, n represents an integer from 2 to 3 inclusive, Z represents a single bond, A represents nitrogen, Q represents nitrogen, M, together with the carbon of pyridyl to which it is bonded, represents thieno, furo, pyrrolo or oxopyrrolo, Its optical isomers and pharmaceutically-acceptable acid or base additional salts thereof, and Medicinal products containing the same which are useful in the treatment of CNS disorders. It being understood that “aryl” is phenyl, naphthyl, dihydronaphthyl, or tetrahydronaphthyl.
摘要翻译: 选自式(I)的化合物:其中:W表示任选取代的萘基,n表示2〜3的整数,Z表示单键,A表示氮,Q表示氮,M表示与 吡咯基,吡咯基或氧吡咯,其光学异构体和药学上可接受的酸或碱的另外的盐,和含有它们的可用于治疗CNS病症的药物。可以理解的是“ 芳基“是苯基,萘基,二氢萘基或四氢萘基。
-
公开(公告)号:US06323217B2
公开(公告)日:2001-11-27
申请号:US09772569
申请日:2001-01-30
申请人: Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
发明人: Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
IPC分类号: A61K314725
CPC分类号: C07D401/12 , C07D405/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04 , C07D495/04
摘要: A compound of formula (I): wherein: R1 represents hydrogen or alkyl, R2a and R2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译: 式(I)化合物:其中:R 1表示氢或烷基,R 2a和R 2b表示选自氢,卤素,烷基,羟基,烷氧基,三卤代烷基,氰基,硝基,氨基,烷基氨基和二烷基氨基的基团,R 3表示氢或 羟基,X表示氧或亚甲基,V表示任选不饱和且任选取代的亚烷基链,U表示键或亚烷基链,W表示选自芳基和杂芳基的基团,这些基团中的每一个可任选地被一个或多个 更多相同或不同的基团,其异构体,其水合物,其溶剂合物及其与药学上可接受的酸的加成盐。 含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。
-
公开(公告)号:US06780868B2
公开(公告)日:2004-08-24
申请号:US10371128
申请日:2003-02-20
申请人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号: C07D40104
CPC分类号: C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要: Compounds of formula (I): wherein: V represents a single bond or a linear or branched (C1-C6)alkylene chain, M represents a single bond or a linear or branched (C1-C6)alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i): X represents carbonyl, G1 represents a linear C3 alkylene chain optionally containing a double bond and/or being optionally substituted by a hydroxyl group, their isomers, their hydrates, their solvates, and additional salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译: 式(I)化合物:其中:V表示单键或直链或支链(C1-C6)亚烷基链,M表示单键或直链或支链(C1-C6)亚烷基链,A和E各自表示 氮或CH,但两组A或E中的至少一个表示氮,W表示式(i)的基团:X表示羰基,G1表示任选含有双键的直链C 3亚烷基链和/或任选取代 羟基,它们的异构体,它们的水合物,它们的溶剂化物,和其药学上可接受的酸的其它盐,以及含有该羟基的药物,可用于治疗已知内皮功能障碍的疾病或病理状况。
-
公开(公告)号:US20080076765A1
公开(公告)日:2008-03-27
申请号:US11904006
申请日:2007-09-25
IPC分类号: A61K31/538 , A61P25/28 , C07D265/34
CPC分类号: C07D498/04
摘要: Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH═CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.
摘要翻译: 式I化合物的反式相对构型:其中:X表示氧原子或NR 2基团,Y表示选自-CH 2 - , - ( CH 2 - )2 - 和-CH-CH-,R 1和R 2,其可以是 相同或不同,各自表示氢原子或选自烷基,环烷基和环烷基烷基的基团,其外消旋形式或旋光异构体形式,以及其与药学上可接受的酸及其水合物的加成盐。 含有该药物的药物可用于治疗涉及多巴胺能系统的中枢神经系统疾病。
-
公开(公告)号:US06908922B2
公开(公告)日:2005-06-21
申请号:US10292358
申请日:2002-11-12
申请人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人: Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号: C07D417/14 , A61K31/00 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/551 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P43/00 , C07D209/08 , C07D211/00 , C07D211/26 , C07D211/58 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/06 , C07D471/04 , C07D491/04 , C07D401/04 , C07D401/14
CPC分类号: C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions ins which endothelial dysfunction is known.
摘要翻译: 式(I)的化合物:其中:V表示单键或亚烷基链,M表示单键或亚烷基链,A和E各自表示氮或CH,但两个基团A或E中的至少一个表示 氮,W表示式(i),(ii)或(iii)的基团:含有该基团的药物,其可用于治疗已知内皮功能障碍的疾病或病理状况。
-
公开(公告)号:US06696469B2
公开(公告)日:2004-02-24
申请号:US09976572
申请日:2001-10-12
申请人: Jean-Louis Peglion , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon , Christophe Poitevin
发明人: Jean-Louis Peglion , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon , Christophe Poitevin
IPC分类号: A61K31445
CPC分类号: C07D401/12 , C07D211/22 , C07D401/14 , C07D405/06 , C07D405/14 , C07D471/04 , C07D491/04
摘要: Compounds of formula (I): wherein: X represents a heterocycle bonded to the remainder of the molecule by a nitrogen atom of the heterocycle, or an —NR2R3 group wherein R2 represents hydrogen or alkyl, and R3 represents aryl, 1,3 dihydro-2H-benzimidazolyl-2-one or alkyl substituted by a heterocycle, n represents zero or 1, R1 represents hydrogen or alkyl, Ra represents a single bond or an alkylene chain, A represents nitrogen or CH, E represents nitrogen or CRe, wherein Re is as defined in the description, Rb represents a single bond or an alkylene chain as defined in the description, W represents aryl or heteroaryl, Their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful for treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译: 式(I)的化合物:其中:X表示通过杂环的氮原子与分子的其余部分键合的杂环,或其中R 2表示氢或烷基且R 3表示芳基的-NR 2 R 3基团, 2H-苯并咪唑基-2-酮或被杂环取代的烷基,n表示0或1,R1表示氢或烷基,Ra表示单键或亚烷基链,A表示氮或CH,E表示氮或CRe,其中Re 如说明书中所定义,R b表示如说明书中定义的单键或亚烷基链,W表示芳基或杂芳基,它们的光学异构体及其与药学上可接受的酸的加成盐,以及含有该酸的药物和含有它们的药物 用于治疗已知内皮功能障碍的疾病或病理状况。
-
-
-
-
-
-
-
-
-